Dr. Budde is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
Dept of Heme and HCT
1500 East Duarte Road
Duarte, CA 91010Phone+1 626-256-4673Fax+1 626-389-3058
Education & Training
University of WashingtonFellowship, Hematology and Medical Oncology, 2006 - 2009
Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 2003 - 2006
Duke UniversityPh.D., 1995 - 2001
Tongji Medical UniversityClass of 1995
Certifications & Licensure
CA State Medical License 2012 - 2026
WA State Medical License 2006 - 2013
Awards, Honors, & Recognition
- Clinical investigator Damon runyon cancer research foundation
Clinical Trials
- Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma Start of enrollment: 2007 Dec 01
- Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL) Start of enrollment: 2013 Aug 01
- Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm Start of enrollment: 2015 Dec 15
- Join now to see all
Publications & Presentations
PubMed
- Impact of prior CAR T-cell therapy on mosunetuzumab efficacy in patients with relapsed or refractory B-cell lymphomas.Elise A Chong, Elicia Penuel, Ellen B Napier, Rachel K Lundberg, Lihua E Budde
Blood Advances. 2025-02-25 - Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after ≥2 prior therapies.Laurie H Sehn, Nancy L Bartlett, Matthew J Matasar, Stephen J Schuster, Sarit E Assouline
Blood. 2025-02-13 - Outcomes of CD19 CAR T in Transformed Indolent Lymphoma Compared to De Novo Aggressive Large B-Cell Lymphoma.Swetha Kambhampati Thiruvengadam, Reid Merryman, Yan Wang, Charles Gaulin, Evandro Bezerra
American Journal of Hematology. 2025-02-01
Abstracts/Posters
- Initial Findings of the Phase 1 Trial of PBCAR0191, a CD19 Targeted Allogeneic CAR-T Cell TherapyLihua E Budde, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Preliminary Results from a Phase 2 Trial of Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed By BV Consolidation in...Lihua E Budde, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- A Phase 1, Open-Label, Multi-Center, Dose Escalation and Dose Expansion Study of NKTR-255 As a Single Agent in Relapsed or Refractory Hematologic Malignancies and in C...Lihua E Budde, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Join now to see all
Press Mentions
City of Hope Clinical and Laboratory Investigators Present New Research at the 60December 4th, 2018
Rituximab Key to Survival After Transplant for Mantle Cell LymphomaNovember 16th, 2017- Mosunetuzumab plus Polatuzumab Vedotin Shows Promise for Patients with Aggressive Relapsed or Refractory Aggressive Large B Cell LymphomaDecember 23rd, 2023
- Join now to see all
Other Languages
- Chinese (Mandarin)
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
